Compare Illumina, Inc. (ILMN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Workiva Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Workiva Inc trades at $68.99 (market cap $3.66B). The key difference: Illumina, Inc. is far larger — about 7.9× Workiva Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | WK | |
|---|---|---|
Market Cap | $28.96B | $3.66B |
Sector | Health | Technology |
52-Week High | $205.10 | $93.31 |
52-Week Low | $91.00 | $44.31 |
Enterprise Value | $30.32B | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Workiva (WK) trades at $65.14, up 4.98% with strong bullish momentum. The stock shows positive technical signals with recent earnings beats and revenue growth of 19% year-over-year in Q2 2026. Analyst consensus is overwhelmingly bullish with 16 buy ratings and an average price target of $69.00. The company's AI platform expansion and strong subscription growth support continued momentum.
Outlook remains positive with improving profitability and strategic AI investments, though high valuation multiples and RSI levels near 70 suggest potential near-term consolidation. Key risks include execution challenges and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
